Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia / Steven M. Paul en The American Journal of Psychiatry, Año 2022 - Vol. 179 - No. 9 (Septiembre)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 9 (Septiembre) . - pp. 611-627 Título : Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia Tipo de documento: texto impreso Autores: Steven M. Paul, Autor ; Samantha E. Yohn, Autor ; Michael Popiolek, Autor Fecha de publicación: 2022 Artículo en la página: pp. 611-627 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Espectro de esquizofrenia - otros trastornos psicóticos, Antipsicóticos, Receptores muscarínicos, Síntomas positivos, negativos y Cognitivos Resumen: Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. An unmet need remains for novel, mechanistically unique, and better tolerated therapeutic agents for treating schizophrenia, especially those that treat not only positive symptoms but also the negative and cognitive symptoms of the disease. Link: ./index.php?lvl=notice_display&id=29389 [artículo] Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia [texto impreso] / Steven M. Paul, Autor ; Samantha E. Yohn, Autor ; Michael Popiolek, Autor . - 2022 . - pp. 611-627. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 9 (Septiembre) . - pp. 611-627 Palabras clave: Espectro de esquizofrenia - otros trastornos psicóticos, Antipsicóticos, Receptores muscarínicos, Síntomas positivos, negativos y Cognitivos Resumen: Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. An unmet need remains for novel, mechanistically unique, and better tolerated therapeutic agents for treating schizophrenia, especially those that treat not only positive symptoms but also the negative and cognitive symptoms of the disease. Link: ./index.php?lvl=notice_display&id=29389

---

1 (1 - 1 / 1)